Chemo-radiation with two immunotherapy drugs for limited-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial combines standard chemotherapy and radiation with two immunotherapy drugs (immune checkpoint inhibitors) to see if they work better together for people with limited-stage small cell lung cancer. It aims to improve outcomes without using strong immune-suppressing medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have small cell lung cancer that has not spread beyond one side of the chest (stage II to III).
- You have not had chemotherapy, radiation, surgery, or immunotherapy before.
- You are in generally good health, able to care for yourself (WHO performance status 0 or 1).
- Your lungs, blood counts, kidneys, and liver are working well enough based on blood and breathing tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with small cell lung cancer who receive radiation therapy combined with other treatments. Researchers will track how well the treatment works and how patients respond over time to help improve future care.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus standard chemotherapy and radiation for people with extensive-stage small cell lung cancer that has only spread to a few places. The goal is to see if this approach can help control the cancer better.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial tests a combination of two immunotherapy drugs (ivonescimab and cadonilimab) plus chemotherapy for people with extensive-stage small cell lung cancer. It's for those who either haven't been treated before or have had only one prior treatment that included a PD-1/PD-L1 drug and it worked for a while.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Hear when a new Small-Cell Lung Cancer (SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.